Sugi Predict

Sugi Predict / Compounds / SCHEMBL161428

SCHEMBL161428

SCHEMBL161428

CCCCCCCCCC(=O)OC1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1

nearest known ligand 0.84

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.70
▸ CYP46A1 Q9Y6A2 2/20 0.69
▸ USP2 O75604 2/20 0.65
▸ LMNA P02545 1/20 0.65
▸ ABCB1 P08183 1/20 0.65
▸ OSBP P22059 1/20 0.65
▸ RORC P51449 1/20 0.65
▸ OSBP2 Q969R2 1/20 0.65
▸ PLA2G2A P14555 1/20 0.62
▸ NPC1 O15118 1/20 0.59
▸ NR1H3 Q13133 2/20 0.58
▸ NPC1L1 Q9UHC9 1/20 0.58
▸ GBA1 P04062 2/20 0.58
▸ UGCG Q16739 2/20 0.58
▸ GBA2 Q9HCG7 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161427 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL4624683 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL19919940 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL17639910 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL22620094 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL21177689 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL126915 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL1667802 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL18310374 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL1697148 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115461096-A Polymer encapsulated drug particles 吉益医疗公司 2022-12-09 — — CN claimed
EP-4025660-A1 THERMOCHROMIC LIQUID CRYSTAL INKS AND COATINGS Sun Chemical Corporation (US) 2022-07-13 — — EP claimed
CN-108815134-B Preparation and application of biological camouflage targeted nano drug delivery system for treating ischemic stroke 中国药科大学 2021-07-13 — — CN claimed
WO-2021046004-A1 THERMOCHROMIC LIQUID CRYSTAL INKS AND COATINGS SUN CHEMICAL CORPORATION (US) 2021-03-11 — — WO claimed
EP-2853264-A1 Nanodispersion Sun Pharma Advanced Research Company Limited (IN) 2015-04-01 — — EP claimed
US-20060115445-A1 Compositions for treating keratin materials comprising electrophilic monomers and liquid crystal agents L'OREAL S.A. (FR) 2006-06-01 — — US claimed
EP-1647259-A1 use for treatment of keratinic materials of compositions comprising electrophilic monomers and agents forming liquid crystals L'OREAL (FR) 2006-04-19 — — EP claimed
US-6328910-B1 FOR IN SITU FORMATION OF AN POLYMERIC CYANOACRYLATE FILM ON MAMMALIAN SKIN WHICH CAN BE USED TO MONITOR THE SURFACE SKIN TEMPERATURE OF MAMMAL MEDLOGIC GLOBAL CORPORATION 2001-12-11 — — US claimed
CN-122079802-A Cationic lipids and compositions thereof — 2026-05-26 — — CN disclosed
CN-118339237-B Reversible thermochromic microcapsule pigments 株式会社百乐 2026-05-12 — — CN disclosed
US-20260102283-A1 PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME GLAUKOS CORP (US) 2026-04-16 — — US disclosed
US-20260026967-A1 MATERIALS AND METHODS FOR PUNCTAL PLUGS GLAUKOS CORP (US) 2026-01-29 — — US disclosed
EP-4041129-B1 PUNCTAL IMPLANTS GLAUKOS CORP (US) 2025-12-03 — — EP disclosed
WO-2025228975-A1 PARTICLES, COMPOSITIONS AND METHODS BioNTech SE (DE) 2025-11-06 — — WO disclosed
EP-0269992-A2 Image recording apparatus and method CANON KABUSHIKI KAISHA (JP) 1988-06-08 — — EP disclosed
EP-0261394-A2 Image recording apparatus CANON KABUSHIKI KAISHA (JP) 1988-03-30 — — EP disclosed
EP-0205083-A2 Image forming method and transfer recording medium therefor CANON KABUSHIKI KAISHA (JP) 1986-12-17 — — EP disclosed
US-4143947-A Method for improving the response time of a display device utilizing a twisted nematic liquid crystal composition GENERAL ELECTRIC COMPANY (US) 1979-03-13 — — US disclosed
US-4035060-A Electro-optic device DAINIPPON PRINTING CO., LTD (JA) 1977-07-12 — — US disclosed
US-3944330-A Electro-optic device DAINIPPON PRINTING CO., LTD. (JA) 1976-03-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060115445-A1 Compositions for treating keratin materials comprising electrophilic monomers and liquid crystal agents KRT18, PRKDC, CUTA POLA1 1396/4885CYP46A1 3561/4885USP2 2505/4885
US-20260102283-A1 PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME SSTR5, CFTR, STARD10 POLA1 3456/4885CYP46A1 3721/4885USP2 703/4885
US-20260026967-A1 MATERIALS AND METHODS FOR PUNCTAL PLUGS GHRHR, TIMCC, GNRHR POLA1 4524/4885CYP46A1 1562/4885USP2 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.